SynthesisAnatolian journal of cardiology2025
Effect of Combined Renal Denervation and Pulmonary Vein Isolation on Atrial Fibrillation: A Systematic Meta-Analysis.
Synthesis in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Repositioning renal denervation in resistant hypertension: evidence-based insights, stratified decision-making, and implementation pathways.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is the most common type of heart arrhythmia. Hypertension (HTN) is known as the most common risk factor for AF. The purpose of this study is to compare clinical results of combined renal denervation (RDN) and pulmonary vein isolation (PVI) in AF patients with HTN.
methodsA systematic search was conducted on patients with AF and HTN, comparing the differences between RDN and PVI with PVI alone. The risk ratio (RR) of categorical variables and the mean difference of continuous variables with a 95% confidence interval were applied.
resultsThis meta-analysis included 10 studies with a total of 875 patients. 420 patients were in the RDN + PVI group (48%) while 455 (52%) were in the PVI group. 694 patients had paroxysmal AF (79.3%) and 181 patients had persistent AF (20.7%). At 12 months follow-up, the treatment of RDN + PVI reduced the overall risk of AF recurrence in HTN patients (RR = 0.64, P < .001, 95% confidence interval [CI]: 0.55-0.75). When pooled, the patients in the RDN + PVI group showed significant mean reductions in systolic blood pressure (BP) (-13.39 mm Hg, P < .001) and diastolic BP (-7.14 mm Hg, P < .001) compared to PVI alone. Meanwhile, PVI + RDN significantly increased the estimated glomerular filtration rate (+8.72 mL/min/1.73 m2, P < .001) compared with PVI alone. There was no significant difference in complications between the 2 groups.
conclusionCombined therapy of RDN + PVI seems more efficacious and superior to PVI alone in treating AF. Further and larger trials are needed to fully prove these outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.